Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gloria Richard-Davis

Reproductive Endocrinology Little Rock, AR Medical Doctor

NPI 1508812850 CMS profile 249870

4301 W Markham St # 783, Little Rock, AR 72205

Open in the dashboard

General payments

$244,942

167 records reported · program years 2019–2025

Research payments

$5,170

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$40,147 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Gloria Richard-Davis of Little Rock, AR is reported in the CMS Open Payments database as having received $244,942 across 167 general payments and $5,170 in research payments paid to them. Separately, studies naming them as principal investigator received $40,147 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,780 16
2024 General $73,624 45
2023 General $68,010 38
2023 Research $5,170 3
2022 General $28,977 23
2021 General $28,490 21
2020 General $6,741 8
2019 General $14,320 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gloria Richard-Davis
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Gloria Richard-Davis were reported at $24,780. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Gloria Richard-Davis Reproductive Endocrinology median Middle half National median
2019 $14,320 $196 $77–$425 $163
2020 $6,741 $81 $35–$182 $114
2021 $28,490 $102 $43–$247 $132
2022 $28,977 $139 $62–$303 $149
2023 $68,010 $141 $65–$285 $160
2024 $73,624 $144 $65–$302 $164
2025 $24,780 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $79,332 59 payments
  2. Astellas Pharma Global Development $45,426 18 payments
  3. Pfizer Inc. $40,228 11 payments
  4. Ferring Pharmaceuticals Inc. $29,721 29 payments
  5. Novo Nordisk Inc $13,809 12 payments
  6. Mitsubishi Tanabe Pharma Development America, Inc. $11,740 11 payments
  7. TherapeuticsMD, Inc. $10,718 10 payments
  8. AbbVie, Inc. $10,587 3 payments
  9. Noven Pharmaceuticals, Inc. $1,300 2 payments
  10. SCYNEXIS, Inc. $1,050 1 payment
  11. Other $1,031 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $150,302 41 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $68,032 18 payments
  3. Travel and Lodging $20,309 51 payments
  4. Food and Beverage $4,435 54 payments
  5. Honoraria $1,800 1 payment
  6. Education $64 2 payments
Products named General payments · program years 2019–2025
  1. Veozah $94,058 56 payments
  2. MYFEMBREE $31,832 9 payments
  3. ANNOVERA $8,545 7 payments
  4. DUAVEE $8,417 3 payments
  5. ORIAHNN $2,100 1 payment
  6. BIJUVA $2,004 1 payment
  7. MENOPUR $268 2 payments
  8. ORILISSA $87 1 payment
  9. GANIRELIX ACETATE $81 4 payments
  10. FOLLISTIM AQ $81 4 payments
  11. Other $302 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Astellas Pharma Global Development $5,170 3 payments

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record